Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07779460) titled 'A Study Comparing Effectiveness of Kesimpta(R) (Ofatumumab) Versus Ocrevus(R) (Ocrelizumab) in Real-world Practice' on Aug. 18.
Study Type: Observational
Primary Sponsor: Novartis Pharmaceuticals
Condition:
Multiple Sclerosis
Recruitment Status: Recruiting
Date of First Enrollment: April 8, 2026
Target Sample Size: 7466
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07779460
Disclaimer: Curated by HT Syndication....